10-Q: DBV Technologies Advances Peanut Allergy Patch, Secures Funding

DBV Technologies reports significant regulatory progress for its Viaskin Peanut patch in both toddler and child age groups, backed by recent financing, despite ongoing operating losses and a going concern warning.

Summary

• DBV Technologies is a clinical-stage biopharmaceutical company developing the Viaskin platform for epicutaneous immunotherapy, with its lead product, Viaskin Peanut patch, targeting peanut allergy.
• The company is pursuing two Biologics License Applications (BLAs) for Viaskin Peanut: one for toddlers aged 1-3 years (original patch) and another for children aged 4-7 years (modified patch).
• For children aged 4-7, the VITESSE Phase 3 study completed subject screening in Q3 2024, with topline results expected in Q4 2025.
• The FDA agreed that safety data from the VITESSE study will be sufficient for a BLA filing in the 4-7 age group, eliminating the need for the COMFORT Children supplemental safety study.
• A BLA submission for the 4-7 age group is planned for H1 2026, potentially accelerating product launch by approximately one year, if approved.
• For toddlers aged 1-3, the FDA has aligned on an Accelerated Approval pathway, with the COMFORT Toddlers supplemental safety study initiated in June 2025 to provide additional safety data.
• The BLA submission for toddlers will be supported by positive efficacy and safety data from the EPITOPE Phase 3 study and additional safety data from COMFORT Toddlers.
• A post-marketing confirmatory effectiveness study for toddlers will be initiated concurrently with the BLA submission and run in parallel to potential commercialization.
• In Europe, the EMA confirmed that the EPITOPE and a positive VITESSE study could support an MAA for a 1-7 year-old indication, but requires a new safety study in toddlers (1-3 years) with the modified patch.
• The company secured financing of up to $306.9 million, including $125.5 million in gross proceeds received on April 7, 2025, and up to $181.4 million from potential warrant exercises.
• An At-The-Market (ATM) Offering was initiated in September 2025 for up to $150.0 million in ADSs, with approximately $30 million in gross proceeds received on October 6, 2025.
• Cash and cash equivalents increased to $69.8 million as of September 30, 2025, from $32.5 million at December 31, 2024, primarily due to financing activities.
• Net loss for the nine months ended September 30, 2025, increased to $102.1 million from $90.9 million in the prior year period.
• Research and development expenses increased by $13.4 million to $83.8 million for the nine months ended September 30, 2025, driven by the COMFORT Toddlers study and pre-commercialization activities.
• The company updated its Manufacturing and Supply Agreement with SANOFI, committing to minimum purchase levels totaling $44.6 million through 2028.
• Management has identified substantial doubt about the company's ability to continue as a going concern for the next 12 months, despite recent financing, as current cash is estimated to fund operations only into Q3 2026.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to significant regulatory progress, including FDA alignment on an Accelerated Approval pathway for toddlers and streamlining the BLA process for older children, which could accelerate market entry. Recent capital raises have also improved liquidity. However, the increased net loss and the explicit 'going concern' warning, coupled with the need for further financing and delays in the European market, temper the overall positive outlook.

Positives

• FDA alignment on an Accelerated Approval pathway for Viaskin Peanut patch in toddlers (1-3 years old) provides a clearer regulatory path.
• Elimination of the COMFORT Children supplemental safety study for the 4-7 year-old age group streamlines the BLA process and could accelerate product launch by approximately one year.
• Completion of subject screening for the VITESSE Phase 3 study in Q3 2024, with topline results expected in Q4 2025, marks significant clinical progress.
• Successful financing rounds, including $125.5 million in gross proceeds received in April 2025 and an additional $30 million from an ATM offering in October 2025, significantly bolstered cash reserves.
• Potential for up to $181.4 million in additional gross proceeds from warrant exercises, contingent on positive VITESSE Phase 3 results, offers substantial future funding.
• Net cash flow used in operating activities decreased by $6.2 million for the nine months ended September 30, 2025, compared to the prior year, indicating some containment of operational cash burn.
• Increased Research Tax Credit by $1.4 million for the nine months ended September 30, 2025, reflecting more eligible R&D activities.

Negatives

• The company reported a net loss of $102.1 million for the nine months ended September 30, 2025, an increase from $90.9 million in the prior year, indicating continued unprofitability.
• Management has identified substantial doubt about the company's ability to continue as a going concern for the next 12 months after the filing date, as current cash is projected to fund operations only into Q3 2026.
• The Marketing Authorization Application (MAA) for Viaskin Peanut in Europe was withdrawn in December 2021, requiring a new safety study in toddlers for potential resubmission, delaying EU market access.
• Research and development expenses increased by $13.4 million to $83.8 million for the nine months ended September 30, 2025, reflecting high ongoing costs for clinical trials and regulatory activities.
• The company remains reliant on external financings to fund operations and future development, with no guarantee of obtaining necessary capital on acceptable terms.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern for the next twelve months after the filing date, as existing cash and cash equivalents are not expected to fund operations through that period.
• The company will need to seek additional capital to fund operations, working capital needs, capital expenditures, and other strategic initiatives beyond Q3 2026.
• There is no assurance that the company will be successful in obtaining necessary future financing or that funds will be available on acceptable terms, which could lead to scaling back operations or relinquishing product rights.
• The VITESSE Phase 3 study's primary endpoint success is crucial for triggering the acceleration of warrant exercise periods, impacting potential future capital raises.
• Regulatory approvals for Viaskin Peanut in both the U.S. and Europe are not guaranteed and are subject to ongoing studies and interactions with regulatory agencies.
• The confirmatory effectiveness study for toddlers (1-3 years old) must be initiated at the time of BLA submission and run in parallel to commercialization, adding post-approval obligations and risks.
• The company is subject to minimum purchase commitments under its Manufacturing and Supply Agreement with SANOFI, totaling $44.6 million through 2028, which could strain liquidity if product launch is delayed or unsuccessful.

Future Outlook

The company anticipates topline results for the VITESSE Phase 3 study in children aged 4-7 in the fourth quarter of 2025. A Biologics License Application (BLA) for this age group is planned for submission in the first half of 2026, potentially accelerating product launch by approximately one year, subject to FDA approval. For toddlers aged 1-3, a BLA submission under the Accelerated Approval program is anticipated, supported by the EPITOPE study and additional safety data from the ongoing COMFORT Toddlers study. A post-marketing confirmatory effectiveness study for toddlers will be initiated at the time of BLA submission and run in parallel to commercialization. In Europe, the company plans to initiate a new toddler safety study to support a potential Marketing Authorization Application (MAA) resubmission for a 1-7 year-old indication. The company estimates its cash and cash equivalents are sufficient to fund operations into the third quarter of 2026, but is actively pursuing additional financing options, including further ATM sales, potential warrant exercises, and strategic transactions, to address its going concern risk.

Management Comments

• Management believes that the company has a reasonable basis for each forward-looking statement contained in this Quarterly Report on Form 10-Q.
• Management evaluates its estimates and assumptions on an ongoing basis, primarily those related to research tax credits, valuation of right-of-use assets, impairment, deferred tax assets, share-based compensation, and contingencies.
• Management is actively pursuing financing options including additional sales under the ATM program, potential warrant exercises, and strategic transactions to address the going concern risk.

Industry Context

DBV Technologies operates in the highly specialized and competitive biopharmaceutical sector, focusing on allergy treatments, specifically peanut allergy. The development of epicutaneous immunotherapy (EPIT) with the Viaskin patch represents a novel approach compared to traditional oral immunotherapies. Regulatory pathways, such as the FDA's Accelerated Approval program, are critical for bringing innovative treatments to market faster, especially for pediatric populations with unmet needs. The company's progress with the Viaskin Peanut patch, particularly the FDA's alignment on accelerated approval for toddlers and the streamlined BLA process for older children, positions it to potentially address a significant market. However, the high costs of clinical development and the need for substantial ongoing financing are typical challenges in the biopharma industry, where companies often incur significant losses for extended periods before potential commercialization.

Comparison to Industry Standards

• The company's approach with epicutaneous immunotherapy (EPIT) using the Viaskin patch is differentiated from other peanut allergy treatments like Aimmune Therapeutics' Palforzia (oral immunotherapy), which was approved by the FDA in 2020 for children aged 4-17. Palforzia requires a strict dose escalation regimen and carries a risk of severe allergic reactions, often requiring administration in a healthcare setting.
• DBV's focus on a non-invasive patch aims to offer a more convenient and potentially safer alternative, minimizing systemic exposure. The FDA's willingness to consider an Accelerated Approval pathway for toddlers (1-3 years old) for Viaskin Peanut suggests recognition of the unmet medical need and the potential benefit of the patch in this younger population, where Palforzia is not approved.
• The requirement for a post-marketing confirmatory study for Accelerated Approval is standard practice, ensuring continued efficacy and safety monitoring post-commercialization, similar to conditions often placed on other novel therapies.
• The withdrawal of the MAA in Europe due to data limitations and the need for a new safety study highlights the stringent and often divergent regulatory requirements between the FDA and EMA, a common challenge for biopharmaceutical companies seeking global market access.

Management Changes

Legal Proceedings

• The company is not currently subject to any material legal proceedings.

Related Party Transactions

• On March 27, 2025, the Board of Directors authorized three new transactions with related parties as part of the financing: a Securities Purchase Agreement with Baker Brothers Advisors LP (a shareholder owning >10% voting rights), a Securities Purchase Agreement with BPIfrance Participations SA (a shareholder with a permanent representative on the Board), and a Registration Rights Agreement with investors, including Baker Brothers Advisors LP and BPIfrance Participations SA.

Stakeholder Impact

• Shareholders: Potential for significant dilution from recent and future capital raises (immediate dilution of 22.4% and maximal dilution of up to 73.7% if all warrants are exercised). The going concern warning raises significant risk for shareholders.
• Patients/Families: Positive regulatory progress for Viaskin Peanut patch offers hope for a new, non-invasive treatment option for peanut allergy in children and toddlers, potentially accelerating access in the US.
• Employees: Changes in executive management (CHRO) and board composition occurred during the quarter. The company's financial stability and going concern risk could impact employee morale and retention.
• Creditors/Investors: The going concern warning and reliance on future financing introduce elevated risk, though recent capital raises provide some short-term liquidity. Warrant holders have a clear trigger for exercise based on VITESSE results.

Next Steps

• Anticipate topline results for the VITESSE Phase 3 study in children ages 4-7 in the fourth quarter of 2025.
• Submit a Biologics License Application (BLA) for the Viaskin Peanut patch in 4-7 year-olds in the first half of 2026.
• Continue enrolling subjects in the COMFORT Toddlers supplemental safety study (1-3 years old) to generate additional safety data.
• Initiate the confirmatory effectiveness study for toddlers (1-3 years old) at the time of BLA submission, to run in parallel with potential commercialization.
• Plan the timing for the initiation of a new safety study in toddlers (1-3 years old) with the modified patch to satisfy European market requirements for MAA resubmission.
• Actively pursue additional financing options, including further sales under the ATM program, potential warrant exercises, and strategic transactions, to fund operations beyond Q3 2026.

Key Dates

Recommendation

The company has made significant regulatory progress for its Viaskin Peanut patch, particularly with FDA alignment on an Accelerated Approval pathway for toddlers and streamlining the BLA process for older children, which are strong positive catalysts. Recent capital raises have also improved the short-term liquidity position. However, the explicit 'going concern' warning, indicating that current cash is only sufficient into Q3 2026, and the continued reliance on future financing, introduce substantial financial risk. The increased net loss also highlights ongoing operational challenges. While the clinical pipeline shows promise, the financial uncertainty and potential for further dilution warrant a 'hold' recommendation. Investors should monitor the VITESSE Phase 3 results (Q4 2025) and the company's ability to secure additional non-dilutive or less dilutive financing to mitigate the going concern risk before considering a 'buy' position. The European market pathway also remains delayed.

Keywords

Viaskin Peanut, Peanut Allergy, Epicutaneous Immunotherapy, EPIT, FDA, BLA, Accelerated Approval, VITESSE, EPITOPE, COMFORT Toddlers, Biologics License Application, Clinical Trials, Biopharmaceutical, Immunotherapy, SEC Filing, 10-Q, Capital Raise, Going Concern, Sanofi